Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer

BMC Molecular Biology

Table 3 Clinical and pathological data on malignant tumour samples where available

Patient Number	Patient Age	Menopausal status	Size (mm)	T	N	Grade	ER	PR	HER2/ neu	Subtype	Metastatic grouping
1	41	Pre	25	2	0		P			Luminal A/B	MF
2	50	Pre	35	2	1	1	P	P	N	Luminal A	MF
3	38	Post	35	2	1	1	P	P	N	Luminal A	MF
4	43	Pre	10	1	0	1	P	P	N	Luminal A	MF
5	49	Post	20	1	1	2	P	N	N	Luminal A	MF
6	78	Post	20	1	1	1	P	P	N	Luminal A	MF
7	51	Post	18	1	0		N		N	LuminalA/Basal	MF
8	75	Post	36	4	1	2	P			Luminal A/B	MF
9	59	Post	50	2	1	3	P	P	N	Luminal A	BM
10	53	Post	85	3	1	3	N	N	N	Basal	MF
11	43	Pre	50	2	1	3	P	N	N	Luminal A	MF
12	69	Post	35	4	2	3	P	P	N	Luminal A	VBM
13	66	Post	12	1	0	3	P	N	N	Luminal A	MF
14	58	Post	20	4	1	2	P	P	N	Luminal A	MF
15	58	Post	15	1	1	2	P	P	N	Luminal A	VBM
16	70	Post	20	1	0	2	P	P	N	Luminal A	MF
17	52	Post	25	4	1	3	P	P	P	Luminal B	VBM
18	78	Post		1	0		P	P	N	Luminal A	BM
19	61	Post	33	2	1	1	P	P	P	Luminal B	BM
20	48	Pre	30	2	1	3	P	P	N	Luminal A	VBM
21	50	Pre	30	2	1	3	N	N		Basal/HER-2	VBM
22	51	Post	20	1		1	P			Luminal A/B	VBM
23	69	Post	40	2	1	2	P	N	N	Luminal A	BM
24	58	Post	21	4		3	N	N	P	HER-2	BM
25	61	Post	35	2	1	3	P	P	N	Luminal A	BM
26	64	Post	15	1	1	2	P	N	P	Luminal B	BM

T, N and M refer to the primary tumor size, nodal status and distant metastases status according to the TNM breast cancer classification system. ER: = oestrogen receptor status; PR: = progesterone receptor status and HER2/neu = v-erb-b2 erythroblastic leukaemia viral oncogene status. Where data was not available for ER, PR and HER-2, possible subtype based on available hormone receptor status is given. Metastatic groupings refer to patient status five years after presentation; patients were either metastases-free (MF), had developed bone metastases (BM) or had developed visceral and bone metastases (VBM).

ISSN: 1471-2199